Holen Sie sich die Stockscreener-App
4.67
11.19%
0.47
Schlusskurs vom Vortag:
$4.20
Offen:
$4.3
24-Stunden-Volumen:
536.70K
Relative Volume:
1.74
Marktkapitalisierung:
$263.69M
Einnahmen:
$2.76M
Nettoeinkommen (Verlust:
$-49.12M
KGV:
-3.1133
EPS:
-1.5
Netto-Cashflow:
$-46.21M
1W Leistung:
-3.91%
1M Leistung:
+23.54%
6M Leistung:
+39.82%
1J Leistung:
-16.90%
1-Tages-Spanne:
$4.29
$4.69
1-Wochen-Bereich:
$4.19
$4.82
52-Wochen-Spanne:
$2.20
$6.30
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Firmenname
Orchestra Biomed Holdings Inc
Sektor
Branche
Telefon
646-343-9298
Adresse
150 UNION SQUARE DRIVE, NEW HOPE
Vergleichen Sie OBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
4.67 | 237.15M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-20 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-03-20 | Eingeleitet | BTIG Research | Buy |
| 2025-01-02 | Eingeleitet | Barclays | Overweight |
| 2024-08-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-25 | Eingeleitet | B. Riley Securities | Buy |
| 2024-01-19 | Eingeleitet | Jefferies | Buy |
| 2023-02-24 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-07 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Orchestra Biomed Holdings Inc Aktie (OBIO) Neueste Nachrichten
TD Cowen initiates Orchestra BioMed stock with Buy rating on novel medical device portfolio - Investing.com Australia
TD Cowen Initiates Orchestra BioMed Holdings at Buy With $15 Price Target - marketscreener.com
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Orchestra BioMed and Medtronic Unveil Promising Hypertension Therapy Advances - Zenopa
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting - Investing News Network
Orchestra BioMed and Medtronic Leadership to Present on Strategic Collaboration for AVIM Therapy at 2025 Innovation in Cardiology Intervention Meeting - Quiver Quantitative
Orchestra BioMed (Nasdaq: OBIO) highlights AVIM Therapy, Virtue SAB at 2025 ICI - Stock Titan
Orchestra BioMed Grants New Hire Stock Options as Clinical Programs Advance - MSN
Analyst Confidence in Orchestra BioMed Holdings (OBIO) High Amid Key Clinical and Strategic Advancements - MSN
What insider trading reveals about Orchestra BioMed Holdings Inc. stockShort Setup & AI Powered Market Trend Analysis - Newser
Orchestra BioMed Enters New Agreement with Terumo for Virtue SAB Device - globallegalchronicle.com
Wall Street Recap: Can Orchestra BioMed Holdings Inc. stock deliver consistent earnings growth2025 Macro Impact & Weekly High Return Stock Forecasts - moha.gov.vn
12 Hot Penny Stocks to Invest in Right Now - Insider Monkey
A better buy-in window may exist right now for Orchestra BioMed Holdings Inc (OBIO) - Setenews
Can Orchestra BioMed Holdings Inc. stock deliver consistent earnings growth2025 Buyback Activity & Fast Momentum Stock Entry Tips - BỘ NỘI VỤ
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
How Orchestra BioMed Holdings Inc. stock performs in high volatility marketsWeekly Trade Report & Verified Short-Term Plans - BỘ NỘI VỤ
Orchestra Biomed announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Orchestra BioMed Grants Stock Options to New Hires as Part of 2025 Inducement Plan - Quiver Quantitative
Orchestra BioMed Holdings Insiders May Regret Not Buying More, Market Cap Hits US$273m - 富途牛牛
Orchestra BioMed’s Big Cash Infusion Sets Stage for High-Stakes Cardiology Trials - MSN
How currency fluctuations impact Orchestra BioMed Holdings Inc. stockDividend Hike & Low Drawdown Trading Strategies - newser.com
Will Orchestra BioMed Holdings Inc. stock outperform tech sector in 2025July 2025 Snapshot & Entry and Exit Point Strategies - newser.com
Orchestra BioMed Study Shows AVIM Therapy Could Transform Care for Hypertensive Heart Disease - MSN
Exit strategy if you’re trapped in Orchestra BioMed Holdings Inc.July 2025 Selloffs & Weekly Watchlist for Consistent Profits - newser.com
Is Orchestra BioMed Holdings Inc. stock supported by strong cash flowsWeekly Stock Summary & Consistent Profit Trade Alerts - newser.com
Is Orchestra BioMed Ready For Landmark Year With Trial Enrollment And Cash Strength? - RTTNews
How sentiment analysis helps forecast Orchestra BioMed Holdings Inc.2025 Volatility Report & Expert Curated Trade Setups - newser.com
Orchestra BioMed Holdings Director David P Hochman Acquires 5,000 Shares - TradingView
Chmn Hochman Buys 5,000 ($20.4K) Of Orchestra BioMed Holdings Inc [OBIO] - TradingView
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity - Stock Titan
Is this a good reentry point in Orchestra BioMed Holdings Inc.Day Trade & Free Verified High Yield Trade Plans - newser.com
Research Analysts Offer Predictions for OBIO FY2025 Earnings - Defense World
Barclays Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Overweight Recommendation - MSN
Will Orchestra BioMed Holdings Inc. stock recover after recent drop2025 Year in Review & Real-Time Stock Price Movement Reports - newser.com
Can Orchestra BioMed Holdings Inc. stock withstand economic slowdownJuly 2025 Retail & Safe Swing Trade Setups - newser.com
Chmn Hochman Surrenders 6,566 Of Orchestra BioMed Holdings Inc [OBIO] - TradingView
Views of Wall Street’s Leading Experts on Orchestra BioMed Holdings Inc - Setenews
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Orchestra BioMed Kicks Off Pivotal U.S. Trial of Non-Coated Sirolimus Balloon - MSN
Orchestra BioMed Secures FDA Breakthrough Designation - TipRanks
Orchestra BioMed Holdings, Inc. Provides Significant Business Updates - TradingView
[8-K] Orchestra BioMed Holdings, Inc. Reports Material Event | OBIO SEC FilingForm 8-K - Stock Titan
Finanzdaten der Orchestra Biomed Holdings Inc-Aktie (OBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):